9xchange is a connected gym
for biopharma assets
we apply the right AI/ML R&D tech to fix/augment them, enabling you to engage with the right partners, transact seamlessly, and more
kiss fewer frogs,
get answers fast
e.g., is this asset available? which buyers are relevant? how do I reach out? can a failed trial be rescued? any exciting new indications?
9xchange accelerates dealmaking, creates options, and is relevant - everything listed is available to transact
Thaminda Ramanayake, fmr VP, Global Head of BD, Oncology, Sanofi
biotech
give your assets new life, or monetize to buy runway
pharma
discover assets you did not know were available, including from your peers
investor, entrepreneur
access available, industry-grade substrate to build or augment companies; help portfolios
ANNOUNCING

BenevolentAI partnership
advanced AI technology identifies new indications for your assets, and as a result, suggests buyers you would not have considered engaging with

LEARN MORE
built by industry leaders across pharma, biotech, VC
the people behind 9xchange. Click the small 9xchange logo to connect with us on 9xchange.
Anat Naschitz is CEO and Co-founder of 9xchange, the connected gym for biopharma assets
anat naschitz
CEO & CO-FOUNDER
investor, company and fund creator
co-founder and partner, OrbiMed Israel. previously senior roles at McKinsey and Apax
Jan Schultink is Co-founder of 9xchange, the connected gym for biopharma assets
jan schultink
CO-FOUNDER
tech entrepreneur. founded and built SlideMagic, international authority in presentation design. senior roles at McKinsey
Jeremy Levin is a member of the Advisory Board of 9xchange, the connected gym for biopharma assets
jeremy levin
ADVISORY BOARD
chairman and CEO, OvidRx. chairman, Opthea. Board member, Lundbeck. vice chair, BIO
CEO, Teva. SVP BD, BMS. global head of BD, Novartis. chair, BIO
Melanie Lee is a member of the Advisory Board of 9xchange, the connected gym for biopharma assets
melanie lee
ADVISORY BOARD
CEO, LifeArc. board member, Sanofi. board trustee, UK Dementia Research. CSO, BTG. CEO, Nighstar (Biogen). CEO, Syntaxin (Ipsen). board, Lundbeck. EVP, UCB
John McHutchison is a member of the Advisory Board of 9xchange, the connected gym for biopharma assets
john mchutchison
ADVISORY BOARD
CEO, Assembly. CSO, head of R&D, Gilead - developed curative drugs for hepatitis C and HBV through approval. AD Duke Clinical Research. Scripps Research Foundation. USC
Paul Biondi is a member of the Advisory Board of 9xchange, the connected gym for biopharma assets
paul biondi
ADVISORY BOARD
executive partner, president, Flagship Pioneering Medicines. boards incl. Seres, Valo
SVP Strategy, BD, BMS. R&D leadership roles, BMS. principal, Mercer
Paul Sekhri is a member of the Advisory Board of 9xchange, the connected gym for biopharma assets
paul sekhri
ADVISORY BOARD
CEO, vTv. 30 boards eg Ipsen, Veeva. CEO Lycera, eGenesis, Cerimon. SVP IC Sanofi. Chief Strategy/BD, Teva. op.partner, TPG Biotech. CBO Ariad. SVP BD&L Novartis
you control what to reveal
you can be specific about your asset or wish without disclosing your strategy - anonymous by default. reveal more to a specific person with increasing trust
AS FEATURED IN


rescue, repurpose, derisk
ai/ml technologies matched with relevant assets to rescue failed trials, repurpose or chart a course. Grow the universe of assets and partners
ANNOUNCING

PhaseV partnership
advanced machine learning tech enables 9xchange members to rescue imperfect data as well as plan and execute future trials adaptively, for better outcomes and cost

LEARN MORE
invitation-only
curated member base of people you would want to work with - your network and ours, covering the entire industry. biotech, pharma, investors, entrepreneurs
APPLY
save time, reduce noise, get more
seamless transaction platform, with all your assets, wishes, deals, data, agreements and contacts in one place. communicate with your team, other 9xchange members, always in context
- support contact privacy news